Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Sage ups share buyback by £200m after strong first half

(Sharecast News) - Enterprise software firm Sage has extended its share buyback plan by £200m after a strong first half, and maintained its growth guidance for the full year despite a "more volatile and uncertain macroeconomic environment". Underlying total revenues rose by 9% year-on-year to £1.24bn in the six months to 31 March, which the company said reflected its high-quality subscription-based recurring revenue model.

All regions contributing to growth: revenues in North America, its biggest division, rose 11% organically to £568m; UKIA underlying revenues were 9% higher at £358m; while revenues in Europe rose 7% to £316m.

Underlying operating profits jumped 16% to £288m, helped by a 1.4 percentage-point improvement in the underlying operating profit margin to 23.2%.

Sage raised its interim dividend per share by 7% to 7.45p, in line with its progressive policy, while the new share purchase programme - which follows a £400m buyback announced in November which will end in June - reflects the company's "strong cash generation, robust financial position, and the board's confidence in Sage's future prospects".

"Sage delivered strong results in the first half of the year, extending our track record of broad-based growth and significant margin expansion. Our performance reflects the strength of our accounting, HR and payroll solutions, underpinned by ongoing investment in our network platform," said chief executive Steve Hare.

Looking ahead, the company continues to expect full-year organic revenue growth of "9% or above", while operating margins are expected to trend upwards in FY25 and beyond.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.